Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06447116 · ClinicalTrials.gov registry record · NA
An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke
A NA study of Acute Ischemic Stroke, sponsored by Jacobs institute.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06447116: Active NA study of Acute Ischemic Stroke, sponsored by Jacobs institute.
NCT06447116 is a NA study of Acute Ischemic Stroke that is active but no longer recruiting, run by Jacobs institute. The registered enrollment target is 15 participants, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06447116, a NA study of Acute Ischemic Stroke, is active but no longer recruiting, sponsored by Jacobs institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The Jacobs Institute is conducting a Sponsor Investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the CGuard Prime™ Carotid Stent in the setting as an acute ischemic stroke.
Primary Outcome
Proportion of subjects with mRS ≤ 2 at 90 days
Conditions Studied
Interventions
- DEVICE CGuard Prime™ Carotid Stent System
Study Locations (1)
New York
- Jacobs Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT06447116 still lists
NCT06447116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 351-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which CGuard Prime™ Carotid Stent System is the first listed.
NCT06447116 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06447116 about?
NCT06447116 is a clinical study titled "An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke". The Jacobs Institute is conducting a Sponsor Investigator study of patients ≥ 18 years to establish safety and preliminary effectiveness in treating extracranial stenosis with the CGuard Prime™ Carotid Stent in the setting as an acute ischemic stroke.
What is the current status of trial NCT06447116?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-01-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06447116 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT06447116?
The interventions under investigation include: CGuard Prime™ Carotid Stent System (DEVICE).
Who is sponsoring clinical trial NCT06447116?
This trial is sponsored by Jacobs institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06447116 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06447116's enrollment target sits among peer trials
15 26th of 25 the lowest of 25 other Acute Ischemic Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
RECRUITING · NA
-
Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)
RECRUITING · NA
-
The Pivotal Study of RapidPulseTM Aspiration System
RECRUITING · NA
-
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
ACTIVE NOT RECRUITING · NA
-
EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)
ACTIVE NOT RECRUITING · NA
-
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI